Zusammenfassung
Erfreulicherweise stehen für die urologischen Tumorerkrankungen zahlreiche medikamentöse Therapieoptionen zur Verfügung. Die Vielzahl der auf unterschiedlichen Wirkmechanismen beruhenden Medikamente bedingen ein hohes Spektrum möglicher unerwünschter Nebenwirkungen. Die häufigsten und relevantesten Komplikationen werden hier besprochen und umfassen Paravasate von Zytostatika, Neutropenie, Anämie, Übelkeit und Erbrechen, Diarrhoe, Stomatitis, Hautveränderungen und immunvermittelte Nebenwirkungen. Diese Nebenwirkungen lassen sich meist durch adäquate Aufklärung der Patienten, Prophylaxe und spezifische Therapien gut kontrollieren.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
Literatur
Bellmunt J, Théodore C, Demkov T, Komyakov B, Sengelov L, Daugaard G, Caty A, Carles J, Jagiello-Gruszfeld A, Karyakin O, Delgado FM, Hurteloup P, Winquist E, Morsli N, Salhi Y, Culine S, von der Maase H (2010) Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 27(27):4454–4461
Bokemeyer C, Aapro MS, Courdi A, Foubert J, Link H, Osterborg A, Repetto L, Soubeyran P (2007) EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. European Organisation for Research and Treatment of Cancer (EORTC) taskforce for the elderly. Eur J Cancer 43(2):258–270
Cassagnol M, McBride A (2009) Management of chemotherapy extravasations. US Pharm 3(9 Oncol Suppl):311
CTCAE v5.0 (2017) https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm
Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Kappeler C, Snapir A, Sarapohja T, Smith MR, ARAMIS Investigators (2019) Darolutamide in nonmetastatic, castration-resistant prostate cancer. N Engl J Med 380(13):1235–1246
Ludwig H, van Belle S, Barrett-Lee P, Birgegard G, Bokemeyer C, Gascon P, Kosmidis P, Krzakowski M, Nortier J, Olmi P, Schneider M, Schrijvers D (2004) The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence and treatment of anemia in cancer patients. Eur J Cancer 40(15):2293–2306
Motzer RJ, Hutson TE, Glen H, Michaelson MD, Molina A, Eisen T, Jassem J, Zolnierek J, Maroto JP, Mellado B, Melichar B, Tomasek J, Kremer A, Kim HJ, Wood K, Dutcus C, Larkin J (2015) Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol 16(15):1473–1482
Schelenz S, Giles D, Abdallah S (2012) Epidemiology, management and economic impact of febrile neutropenia in oncology patients receiving routine care at a regional UK cancer centre. Ann Oncol 23(7):1889–1893
Schmoll HJ, Höffken K, Possinger K (2006) Kompendium internistische Onkologie, Standards in Diagnostik und Therapie. Springer Verlag, Berlin, Heidelberg
Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, Olmos D, Mainwaring PN, Lee JY, Uemura H, Lopez-Gitlitz A, Trudel GC, Espina BM, Shu Y, Park YC, Rackoff WR, Yu MK, Small EJ (2018) SPARTAN investigators. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med 378(15):1408–1418
Taplitz RA, Kennedy EB, Bow EJ, Crews J, Gleason C, Hawley DK, Langston AA, Nastoupil LJ, Rajotte M, Rolston K, Strasfeld L, Flowers CR (2018) Outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice guideline update. JCO 36(14):1443–1453
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature
About this chapter
Cite this chapter
Bögemann, M. (2021). Medikamentöse Tumortherapie. In: Kranz, J., Anheuser, P., Steffens, J.A. (eds) Komplikationen in der Urologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-60625-4_10
Download citation
DOI: https://doi.org/10.1007/978-3-662-60625-4_10
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-60624-7
Online ISBN: 978-3-662-60625-4
eBook Packages: Medicine (German Language)